Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 140

Similar articles for PubMed (Select 22812444)

1.

Synthesis and evaluation of a peptide targeted small molecular Gd-DOTA monoamide conjugate for MR molecular imaging of prostate cancer.

Wu X, Burden-Gulley SM, Yu GP, Tan M, Lindner D, Brady-Kalnay SM, Lu ZR.

Bioconjug Chem. 2012 Aug 15;23(8):1548-56. doi: 10.1021/bc300009t. Epub 2012 Aug 1.

2.

MR molecular imaging of prostate cancer with a peptide-targeted contrast agent in a mouse orthotopic prostate cancer model.

Tan M, Burden-Gulley SM, Li W, Wu X, Lindner D, Brady-Kalnay SM, Gulani V, Lu ZR.

Pharm Res. 2012 Apr;29(4):953-60. doi: 10.1007/s11095-011-0635-y. Epub 2011 Dec 3.

3.

MR molecular imaging of prostate cancer with a small molecular CLT1 peptide targeted contrast agent.

Wu X, Lindner D, Yu GP, Brady-Kalnay S, Lu ZR.

J Vis Exp. 2013 Sep 3;(79). doi: 10.3791/50565.

4.

Synthesis and evaluation of a targeted nanoglobular dual-modal imaging agent for MR imaging and image-guided surgery of prostate cancer.

Tan M, Ye Z, Lindner D, Brady-Kalnay SM, Lu ZR.

Pharm Res. 2014 Jun;31(6):1469-76. doi: 10.1007/s11095-013-1008-5. Epub 2013 Mar 8.

PMID:
23471641
5.

Peptide-targeted Nanoglobular Gd-DOTA monoamide conjugates for magnetic resonance cancer molecular imaging.

Tan M, Wu X, Jeong EK, Chen Q, Lu ZR.

Biomacromolecules. 2010 Mar 8;11(3):754-61. doi: 10.1021/bm901352v.

6.

Gadolinium-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-Lys-polyethylene glycol-CGLIIQKNEC (CLT1).

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2012 Sep 15 [updated 2012 Dec 06].

7.

Gadolinium-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid monoamide-G2 nanoglobule-CGLIIQKNEC (CLT1)-Cy5.

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2013 Apr 21 [updated 2013 Jun 13].

8.

Manganese(II)-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-G3 nanoglobule-CGLIIQKNEC (CLT1).

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2012 Sep 15 [updated 2012 Dec 06].

9.

Gadolinium-1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-G3 nanoglobule-CGLIIQKNEC (CLT1).

Leung K.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2012 Oct 01 [updated 2012 Dec 06].

10.

Synthesis and evaluation of a polydisulfide with Gd-DOTA monoamide side chains as a biodegradable macromolecular contrast agent for MR blood pool imaging.

Ye Z, Wu X, Tan M, Jesberger J, Grisworld M, Lu ZR.

Contrast Media Mol Imaging. 2013 May-Jun;8(3):220-8. doi: 10.1002/cmmi.1520.

11.

An effective targeted nanoglobular manganese(II) chelate conjugate for magnetic resonance molecular imaging of tumor extracellular matrix.

Tan M, Wu X, Jeong EK, Chen Q, Parker DL, Lu ZR.

Mol Pharm. 2010 Aug 2;7(4):936-43. doi: 10.1021/mp100054m.

12.

A peptide targeted contrast agent specific to fibrin-fibronectin complexes for cancer molecular imaging with MRI.

Ye F, Wu X, Jeong EK, Jia Z, Yang T, Parker D, Lu ZR.

Bioconjug Chem. 2008 Dec;19(12):2300-3. doi: 10.1021/bc800211r. Erratum in: Bioconjug Chem. 2009 Feb 18;20(2):402. Wu, Xueming [added].

13.

Peptide targeted high-resolution molecular imaging of prostate cancer with MRI.

Wu X, Yu G, Lindner D, Brady-Kalnay SM, Zhang Q, Lu ZR.

Am J Nucl Med Mol Imaging. 2014 Jul 15;4(6):525-36. eCollection 2014.

14.

Peptide targeted tripod macrocyclic Gd(III) chelates for cancer molecular MRI.

Zhou Z, Wu X, Kresak A, Griswold M, Lu ZR.

Biomaterials. 2013 Oct;34(31):7683-93. doi: 10.1016/j.biomaterials.2013.06.057. Epub 2013 Jul 14.

15.

Synthesis and evaluation of globular Gd-DOTA-monoamide conjugates with precisely controlled nanosizes for magnetic resonance angiography.

Kaneshiro TL, Jeong EK, Morrell G, Parker DL, Lu ZR.

Biomacromolecules. 2008 Oct;9(10):2742-8. doi: 10.1021/bm800486c. Epub 2008 Sep 5.

16.

Synthesis and evaluation of nanoglobular macrocyclic Mn(II) chelate conjugates as non-gadolinium(III) MRI contrast agents.

Tan M, Ye Z, Jeong EK, Wu X, Parker DL, Lu ZR.

Bioconjug Chem. 2011 May 18;22(5):931-7. doi: 10.1021/bc100573t. Epub 2011 Apr 19.

17.

Molecular MRI of atherosclerotic plaque progression in an ApoE(-/-) mouse model with a CLT1 peptide targeted macrocyclic Gd(III) chelate.

Wu X, Balu N, Li W, Chen Y, Shi X, Kummitha CM, Yu X, Yuan C, Lu ZR.

Am J Nucl Med Mol Imaging. 2013 Sep 19;3(5):446-55. eCollection 2013.

18.

cRGD peptide-conjugated icosahedral closo-B12(2-) core carrying multiple Gd3+-DOTA chelates for α(v)β3 integrin-targeted tumor imaging (MRI).

Goswami LN, Ma L, Cai Q, Sarma SJ, Jalisatgi SS, Hawthorne MF.

Inorg Chem. 2013 Feb 18;52(4):1701-9. doi: 10.1021/ic302340c. Epub 2013 Feb 7.

19.

Evaluation of CLT1-(Gd-DTPA) for Cancer MR Molecular Imaging in a Mouse Breast Cancer Model.

Ye F, Jeong EK, Parker D, Lu ZR.

Bo Pu Xue Za Zhi. 2011;2(5):325-330.

20.

Molecular MR imaging of neovascular progression in the Vx2 tumor with αvβ3-targeted paramagnetic nanoparticles.

Schmieder AH, Winter PM, Williams TA, Allen JS, Hu G, Zhang H, Caruthers SD, Wickline SA, Lanza GM.

Radiology. 2013 Aug;268(2):470-80. doi: 10.1148/radiol.13120789. Epub 2013 Jun 14.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk